IDegLira for type 2 diabetes: a systematic review and meta-analysis

• Published in: Endocrine 2024-03, Vol.83 (3), p.648-658
• Main Authors: Liu, Yang, Li, Xuejing, Zheng, Yingying, Wang, Xiaoli, Wang, Xianying
• Format: Article
• Language: English
• Subjects: Adverse events; Blood pressure; Clinical trials; Diabetes; Diabetes mellitus (non-insulin dependent); Endocrinology; Glucagon; Glucagon-like peptide 1; Glucose; Hemoglobin; Humanities and Social Sciences; Hypoglycemia; Insulin; Internal Medicine; Medicine; Medicine & Public Health; Meta-analysis; multidisciplinary; Original Article; Science; Systematic review; Weight
• ISSN: 1559-0100; 1355-008X; 1559-0100
• DOI: 10.1007/s12020-023-03543-z

Objectives IDegLira is a novel fixed-ratio soluble combination of insulin degludec and the glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide approved for type 2 diabetes (T2D) patients. Individual trials have assessed the clinical profile of IDegLira vs different comparators. We conducted a systematic review and meta-analysis to evaluate the efficacy and safety of IDegLira for T2D. Methods PubMed, Embase, Cochrane Library and ClinicalTrials.gov were searched from inception to August 15, 2023. The primary outcomes included change from baseline in haemoglobin A1c (HbA1c) and body weight. Risk ratios (RR), mean differences (MD), and 95% confidence intervals (CI) were calculated to evaluate the outcomes. Results This meta-analysis identified 1044 citations, and included 13 eligible trials, enroling 7773 patients. Compared with the control groups, IDegLira was optimal in change in HbA1c, percentage of patients achieving HbA1c